mRNA-脂质纳米颗粒疫苗平台的未来考量。
Future considerations for the mRNA-lipid nanoparticle vaccine platform.
机构信息
Thomas Jefferson University, Department of Microbiology and Immunology, 233 South 10th Street, Philadelphia, PA 19107, United States.
Thomas Jefferson University, Department of Microbiology and Immunology, 233 South 10th Street, Philadelphia, PA 19107, United States.
出版信息
Curr Opin Virol. 2021 Jun;48:65-72. doi: 10.1016/j.coviro.2021.03.008. Epub 2021 Apr 24.
Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin Karikó and Drew Weissman at the University of Pennsylvania are a promising new vaccine platform used by two of the leading vaccines against coronavirus disease in 2019 (COVID-19). However, there are many questions regarding their mechanism of action in humans that remain unanswered. Here we consider the immunological features of LNP components and off-target effects of the mRNA, both of which could increase the risk of side effects. We suggest ways to mitigate these potential risks by harnessing dendritic cell (DC) biology.
基于含有 mRNA 的脂质纳米颗粒（LNPs）的疫苗由宾夕法尼亚大学的 Katalin Karikó 和 Drew Weissman 首创，是一种有前途的新型疫苗平台，被用于两种针对 2019 年冠状病毒病（COVID-19）的领先疫苗。然而，关于它们在人体中的作用机制仍有许多问题尚未得到解答。在这里，我们考虑了 LNP 成分的免疫学特征和 mRNA 的脱靶效应，这两者都可能增加副作用的风险。我们提出了利用树突状细胞（DC）生物学来减轻这些潜在风险的方法。
Zotero 插件